Board approves Q2 results, two acquisitions; standalone profit dips 63%

Profit growth above 25%Negative operating cash flowResults View source PDF Explain this filing

ENTERO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.9%Reaction day

₹1136.50

prior close

₹1156.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%+1.0% vs market

Retailing peers, median of 57sector · industry level-0.9%+1.8% vs sector

On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 1.8 pts more than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-1.9

15m

-1.9

30m

-2.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.9-0.1+1.0-0.9+1.8

Next day

-0.3-0.2-0.1-0.9+0.6

+0.3+0.4-0.1-0.7+1.0

-0.4-0.4-0.0-1.3+0.9

-4.3-0.6-3.7-1.3-3.0

-5.9-0.9-5.0-2.0-3.8

-7.4-3.0-4.4-3.7-3.8

15d

-8.5-3.9-4.6-5.3-3.2

-11.6-4.8-6.8-5.4-6.2

+7.4-7.8+15.2-8.8+16.2

+0.4-7.2+7.6-12.4+12.8

UpDownMarket · Nifty Microcap 250Sector · Retailing peers, median of 57Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q2 FY26 results (unaudited). Standalone revenue fell 26% YoY to Rs 832.21M; standalone PAT dropped 63% to Rs 56.97M. Consolidated revenue grew 21% to Rs 15,709.48M; consolidated PAT rose 41% to Rs 366M. Board approved acquisition of 80% stake in Bioaide Technologies and 51% stake in Anand Chemiceutics (subject to due diligence). Allotted 2,030 ESOP shares. Consolidated H1 operating cash flow remained negative at Rs 672.73M.

Likely market impact

Mixed bag: strong consolidated growth on acquisitions but weak standalone; deal pipeline expands footprint but cash burn continues.